Skip to main content

Table 4 Delayed bleeding risk according to the two different sensitivity analyses performed

From: Incidence of delayed bleeding in patients on antiplatelet therapy after mild traumatic brain injury: a systematic review and meta-analysis

Study MTBI Sensitivity
ANTONI_2019 NA 1.85% (0.23–6.53%)
BATTLE_2017 NA 2.27% (0.06–12.02%)
CHENOWETH_2018 NA 7.11% (3.94–11.64%)
ERNSTBRUNNER_2016 1.05% (0.29–2.66%) 1.05% (0.29–2.66%)
GALLIAZZO_2019 1.53% (0.19–5.41%) 1.53% (0.19–5.41%)
GANETSKY_2017 NA 3.61% (2.30–5.37%)
HILL_2018 NA 3.29% (1.33–6.65%)
HUANG_2019 NA 2.52% (0.52–7.19%)
MANN_2018 NA 0.00% (0.00–3.18%)
NISHIJIMA_2012 0.00% (0.00–1.53%) 1.23% (0.26–3.57%)
PECK_2011 NA 0.00% (0.00–3.52%)
SCANTLING_2017 1.21% (0.15–4.31%) 1.2% (0.15–4.28%)
STANITSAS_2016 NA 0.00% (0.00–8.81%)
SWAP_2016 NA 2.31% (0.85–4.95%)
TAUBER_2009 4.00% (1.10–9.93%) 4.00% (1.10–9.93%)
TAYLOR_2012 NA 0.00% (0.00–4.25%)
No. studies 5 16
DB mean estimated risk 1.04% (0.15–2.49%) 1.70% (0.93–2.67%)
p value for heterogeneity p = 0.0334 p = 0.0012
I2 statistic 62% 60%
  1. The results are presented as the mean estimates of delayed bleeding risk and 95% confidence intervals (in parentheses). GCS = Glasgow Coma Scale; MTBI = mild traumatic brain injury: includes only studies enrolling patients with TBI and a GCS ≥ 13; Sensitivity = includes all the studies considering unexplained deaths and patients lost at follow-up as events (i.e. delayed bleeding); No. studies = number of the studies included in the analysis; NA = not assessed in the corresponding original study